Drug intelligence / Profile preview

rolistobart

Development stage: Phase 2
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**Rolistobart** is a humanized IgG4-κ monoclonal antibody that targets **LILRB4** (also known as CD85k or leukocyte immunoglobulin-like receptor B4), an inhibitory receptor expressed on myeloid cells in the tumor microenvironment. By blocking LILRB4, it functions as an **immunostimulant** and **antineoplastic agent**, promoting immune activation against tumors and inhibiting tumor growth. Developed by Merck (as MK-0482), it is an investigational drug currently in **clinical development**, notably for **advanced non-small cell lung cancer (NSCLC)**.

Other names: anti–ILT3 monoclonal antibodyanti-LILRB4 monoclonal antibodyanti-LILRB-4 monoclonal antibodyanti-LILRB 4 monoclonal antibody

Targets

LILRB4

Beyond the preview

Go deeper on rolistobart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rolistobart.

Explore the full profile